Vantictumab, formerly known as OMP18R5, represents a novel monoclonal body designed with specifically inhibit bone associated protein 18R5. This approach is actively studied by the company for potential applications in https://dirstop.com/story28103225/vantictumab-the-detailed-investigation-into-the-engineered-immune-agent